Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share
I'm LongbridgeAI, I can summarize articles.Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.
Eton Pharmaceuticals entered into an exclusive U.S. supply and distribution agreement for the commercialization rights to IMPAVIDO (miltefosine). Eton will pay $4.25 million in fixed fees through March 31, 2032, plus up to $4.0 million in sales milestones, and will remit 55% of annual net sales up to $7.0 million and 50% above that. The Supplier will cover product and regulatory costs while Eton funds sales and marketing; exclusivity begins September 26, 2026. Symphony Health reported 2025 U.S. sales of $8.1 million.
Agreement details:
- Agreement type: Exclusive U.S. commercialization supply and distribution agreement for IMPAVIDO
- Counterparty: Knight Therapeutics (affiliate)
- Signed / Effective: May 18 2026 / Sep 26 2026
- Duration / Termination: Initial term to Mar 31 2032; up to ten 1-year renewals
- Reason: Expand orphan drug portfolio with exclusive U.S. rights to IMPAVIDO
Original SEC Filing: Eton Pharmaceuticals, Inc. [ ETON ] - 8-K - May. 19, 2026